Role of the EZH2/miR-200 axis in STAT3-mediated OSCC invasion Corrigendum in /10.3892/ijo.2023.5528

Wang,Yu; Guo,Wenyu; Li,Zhaoqing; Wu,Yansheng; Jing,Chao; Ren,Yu; Zhao,Minghui; Kong,Lingping; Zhang,Chao; Dong,Jiabin; Shuang,Yu; Sun,Shanshan; Chen,Jinliang; Wu,Chuanqiang; Qiao,Yu; Qu,Xin; Wang,Xudong; Zhang,Lun; Jin,Rui; Zhou,Xuan

doi:10.3892/ijo.2018.4293

Role of the EZH2/miR-200 axis in STAT3-mediated OSCC invasion

Corrigendum in 10.3892/ijo.2023.5528

Authors:
- Yu Wang
- Wenyu Guo
- Zhaoqing Li
- Yansheng Wu
- Chao Jing
- Yu Ren
- Minghui Zhao
- Lingping Kong
- Chao Zhang
- Jiabin Dong
- Yu Shuang
- Shanshan Sun
- Jinliang Chen
- Chuanqiang Wu
- Yu Qiao
- Xin Qu
- Xudong Wang
- Lun Zhang
- Rui Jin
- Xuan Zhou
View Affiliations

Affiliations: Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute; National Clinical Research Center of Cancer, Tianjin 300060, P.R. China, Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, P.R. China, Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
Published online on: February 28, 2018 https://doi.org/10.3892/ijo.2018.4293
Pages: 1149-1164
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abnormal activation of signal transducer and activator of transcription 3 (STAT3) serves a pivotal role in oral squamous cell carcinoma (OSCC) tumor cell invasion into normal tissues or distant organs. However the downstream regulatory network of STAT3 signaling remains unclear. The present study aimed to investigate the potential mechanism underlying how STAT3 triggers enhancer of zeste homolog 2 (EZH2) expression and inhibits microRNA (miR)-200a/b/429 expression in SCC25 and SCC15 cells in vitro and in vivo. Western blotting and reverse transcription-quantitative polymerase chain reaction were performed to detect expression, and numerous functional tests were conducted to explore cancer metastasis. The results indicated that when STAT3 signaling activity was attenuated by Stattic or enhanced with a STAT3 plasmid, the EZH2/miR-200 axis was markedly altered, thus resulting in modulation of the invasion and migration of OSCC cell lines. In addition, loss of function of EZH2 compromised the oncogenic role of STAT3 in both cell lines. F-actin morphology and the expression of epithelial-mesenchymal transition markers were also altered following disruption of the STAT3/EZH2/miR-200 axis. An orthotopic tumor model derived from SCC15 cells was used to confirm that targeting STAT3 or EZH2 suppressed OSCC invasion in vivo. In conclusion, the EZH2/miR-200 axis was revealed to mediate antitumor effects by targeting STAT3 signaling; these findings may provide a novel therapeutic strategy for the treatment of OSCC.

View Figures

View References

1	Pulte D and Brenner H: Changes in survival in head and neck cancers in the late 20th and early 21st century: A period analysis. Oncologist. 15:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
2	Lam L, Logan RM and Luke C: Epidemiological analysis of tongue cancer in South Australia for the 24-year period, 1977–2001. Aust Dent J. 51:16–22. 2006. View Article : Google Scholar : PubMed/NCBI
3	Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, van Trappen P, Cox G, Harris AL and Jackson DG: Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 62:1315–1320. 2002.PubMed/NCBI
4	Patel V, Marsh CA, Dorsam RT, Mikelis CM, Masedunskas A, Amornphimoltham P, Nathan CA, Singh B, Weigert R, Molinolo AA, et al: Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res. 71:7103–7112. 2011. View Article : Google Scholar : PubMed/NCBI
5	Roepman P, Kemmeren P, Wessels LF, Slootweg PJ and Holstege FC: Multiple robust signatures for detecting lymph node metastasis in head and neck cancer. Cancer Res. 66:2361–2366. 2006. View Article : Google Scholar : PubMed/NCBI
6	Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV: Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 12:5055–5063. 2006. View Article : Google Scholar : PubMed/NCBI
7	Giraud S, Bienvenu F, Avril S, Gascan H, Heery DM and Coqueret O: Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J Biol Chem. 277:8004–8011. 2002. View Article : Google Scholar : PubMed/NCBI
8	Nakashima K, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, Kawabata M, Miyazono K and Taga T: Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science. 284:479–482. 1999. View Article : Google Scholar : PubMed/NCBI
9	Margueron R and Reinberg D: The Polycomb complex PRC2 and its mark in life. Nature. 469:343–349. 2011. View Article : Google Scholar : PubMed/NCBI
10	Ciferri C, Lander GC, Maiolica A, Herzog F, Aebersold R and Nogales E: Molecular architecture of human polycomb repressive complex 2. Elife. 1:e000052012. View Article : Google Scholar : PubMed/NCBI
11	Lin YW, Ren LL, Xiong H, Du W, Yu YN, Sun TT, Weng YR, Wang ZH, Wang JL, Wang YC, et al: Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer. J Pathol. 230:277–290. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, et al: Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 23:839–852. 2013. View Article : Google Scholar : PubMed/NCBI
13	Methylation by EZH2 activates STAT3 in glioblastoma. Cancer Discov. 3:OF212013.PubMed/NCBI
14	Xue X, Zhang Y, Zhi Q, Tu M, Xu Y, Sun J, Wei J, Lu Z, Miao Y and Gao W: MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. Cell Commun Signal. 12:622014. View Article : Google Scholar : PubMed/NCBI
15	Sossey-Alaoui K, Bialkowska K and Plow EF: The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J Biol Chem. 284:33019–33029. 2009. View Article : Google Scholar : PubMed/NCBI
16	Sun N, Zhang Q, Xu C, Zhao Q, Ma Y, Lu X, Wang L and Li W: Molecular regulation of ovarian cancer cell invasion. Tumour Biol. 35:11359–11366. 2014. View Article : Google Scholar : PubMed/NCBI
17	Holzner S, Senfter D, Stadler S, Staribacher A, Nguyen CH, Gaggl A, Geleff S, Huttary N, Krieger S, Jäger W, et al: Colorectal cancer cell-derived microRNA200 modulates the resistance of adjacent blood endothelial barriers in vitro. Oncol Rep. 36:3065–3071. 2016. View Article : Google Scholar : PubMed/NCBI
18	Xiao P, Liu W and Zhou H: miR-200b inhibits migration and invasion in non-small cell lung cancer cells via targeting FSCN1. Mol Med Rep. 14:1835–1840. 2016. View Article : Google Scholar : PubMed/NCBI
19	Yuan D, Xia H, Zhang Y, Chen L, Leng W, Chen T, Chen Q, Tang Q, Mo X, Liu M, et al: P-Akt/miR 200 signaling regulates epithelial-mesenchymal transition, migration and invasion in circulating gastric tumor cells. Int J Oncol. 45:2430–2438. 2014. View Article : Google Scholar : PubMed/NCBI
20	Chen J, Wang L, Matyunina LV, Hill CG and McDonald JF: Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol. 121:200–205. 2011. View Article : Google Scholar : PubMed/NCBI
21	Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI
22	Park SM, Gaur AB, Lengyel E and Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
23	Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K, Kang C and Zhang Q: DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Lett. 359:198–205. 2015. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Lee TK, Poon RT, Wo JY, Ma S, Guan XY, Myers JN, Altevogt P and Yuen AP: Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 67:8800–8809. 2007. View Article : Google Scholar : PubMed/NCBI
26	Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, Weiss LM, Digiusto D, Yu H, Forman S and Jove R: STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res. 71:3182–3188. 2011. View Article : Google Scholar : PubMed/NCBI
27	Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 114:2733–2743. 2009. View Article : Google Scholar : PubMed/NCBI
28	Feldman AT and Wolfe D: Tissue processing and hematoxylin and eosin staining. Methods Mol Biol. 1180:31–43. 2014. View Article : Google Scholar : PubMed/NCBI
29	Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y and Kroemer G: STAT3 inhibition enhances the therapeutic efficacy of immunogenic chemotherapy by stimulating type 1 interferon production by cancer cells. Cancer Res. 75:3812–3822. 2015. View Article : Google Scholar : PubMed/NCBI
30	Sharma V, Purkait S, Takkar S, Malgulwar PB, Kumar A, Pathak P, Suri V, Sharma MC, Suri A, Kale SS, et al: Analysis of EZH2: micro-RNA network in low and high grade astrocytic tumors. Brain Tumor Pathol. 33:117–128. 2016. View Article : Google Scholar : PubMed/NCBI
31	Chen J, Lan T, Zhang W, Dong L, Kang N, Zhang S, Fu M, Liu B, Liu K and Zhan Q: Feed-forward reciprocal activation of PAFR and STAT3 regulates epithelial-mesenchymal transition in non-small cell lung cancer. Cancer Res. 75:4198–4210. 2015. View Article : Google Scholar : PubMed/NCBI
32	Loncle C, Bonjoch L, Folch-Puy E, Lopez-Millan MB, Lac S, Molejon MI, Chuluyan E, Cordelier P, Dubus P, Lomberk G, et al: IL17 Functions through the Novel REG3β-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer. Cancer Res. 75:4852–4862. 2015. View Article : Google Scholar : PubMed/NCBI
33	Baumgart S, Chen NM, Siveke JT, König A, Zhang JS, Singh SK, Wolf E, Bartkuhn M, Esposito I, Heßmann E, et al: Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Cancer Discov. 4:688–701. 2014. View Article : Google Scholar : PubMed/NCBI
34	Kesselring R, Glaesner J, Hiergeist A, Naschberger E, Neumann H, Brunner SM, Wege AK, Seebauer C, Köhl G, Merkl S, et al: IRAK-M expression in tumor cells supports colorectal cancer progression through reduction of antimicrobial defense and stabilization of STAT3. Cancer Cell. 29:684–696. 2016. View Article : Google Scholar : PubMed/NCBI
35	Fan TF, Bu LL, Wang WM, Ma SR, Liu JF, Deng WW, Mao L, Yu GT, Huang CF, Liu B, et al: Tumor growth suppression by inhibiting both autophagy and STAT3 signaling in HNSCC. Oncotarget. 6:43581–43593. 2015. View Article : Google Scholar : PubMed/NCBI
36	Zhou X, Ren Y, Liu A, Han L, Zhang K, Li S, Li P, Li P, Kang C, Wang X, et al: STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol Rep. 31:2173–2180. 2014. View Article : Google Scholar : PubMed/NCBI
37	Zhou X, Ren Y, Liu A, Jin R, Jiang Q, Huang Y, Kong L, Wang X and Zhang L: WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis. Sci Rep. 4:74612014. View Article : Google Scholar : PubMed/NCBI
38	Zhou X, Ren Y, Kong L, Cai G, Sun S, Song W, Wang Y, Jin R, Qi L, Mei M, et al: Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC. Oncotarget. 6:33720–33732. 2015. View Article : Google Scholar : PubMed/NCBI
39	Dasgupta M, Dermawan JK, Willard B and Stark GR: STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc Natl Acad Sci USA. 112:3985–3990. 2015. View Article : Google Scholar : PubMed/NCBI
40	Pan YM, Wang CG, Zhu M, Xing R, Cui JT, Li WM, Yu DD, Wang SB, Zhu W, Ye YJ, et al: STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. Mol Cancer. 15:792016. View Article : Google Scholar : PubMed/NCBI
41	Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, et al: Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 128:1327–1334. 2011. View Article : Google Scholar
42	Manavalan TT, Teng Y, Litchfield LM, Muluhngwi P, Al-Rayyan N and Klinge CM: Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One. 8:e623342013. View Article : Google Scholar : PubMed/NCBI
43	Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, Brait M, Hoque MO, Ling S, Bedi A, et al: The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res. 74:3995–4005. 2014. View Article : Google Scholar : PubMed/NCBI
44	Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F and Esteller M: Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene. 31:2062–2074. 2012. View Article : Google Scholar :
45	Enkhbaatar Z, Terashima M, Oktyabri D, Tange S, Ishimura A, Yano S and Suzuki T: KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. Cell Cycle. 12:2100–2112. 2013. View Article : Google Scholar : PubMed/NCBI